PIK3CA and breast neoplasm: Additionally, the phase II LORELEI trial found no significant difference in pCR between combined taselisib and letrozole versus letrozole alone as neoadjuvant treatment in patients with stage I–III, operable, ER+/HER2− negative (HER2−) breast tumors with or without PIK3CA mutation [40].